Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

14022 ATTUNE Cementless RP Klinische Leistungsbewertung

2. November 2026 aktualisiert von: DePuy Orthopaedics

Multizentrische klinische Bewertung der ATTUNE zementfreien rotierenden Plattform-Totalendoprothetik des Knies

The primary objective of this study is to examine the change from pre-operative baseline to two year postoperative functional performance improvement for the ATTUNE primary, cementless TKA RP system as measured with the KOOS questionnaire (KOOS-ADL sub-score). This will be carried out for two configurations: cruciate retaining rotating platform (ATTUNE Cementless CR RP) and posterior stabilized rotating platform (ATTUNE Cementless PS RP).

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

The secondary objectives of this study are:

  • Evaluate change from preoperative baseline in post-operative outcomes using additional patient reported measures at 2 years: PKIP (overall and sub-scores), KOOS (overall and sub-scores), AKS and EQ-5D-3L.
  • Evaluate change from preoperative baseline in pain and satisfaction over time as measured using a modified VAS Pain Score (discrete numbers rather than a continual scale) at 2yr.
  • Evaluate type and frequency of Adverse Events
  • Evaluate survivorship of the ATTUNE Primary Cementless TKA system for the CR RP and PS RP configurations using Kaplan-Meier survival analysis at 2yr and 5yrs.
  • Evaluate primary, cementless ATTUNE TKA fixation through zonal radiographic analysis of the bone-implant interface at 6wk, 6mo, 1yr, and 2yr after surgery.
  • Evaluate any changes in anatomic tibiofemoral, femoral component and tibial component alignment at 2 years compared to the first postoperative radiographs.

Studientyp

Interventionell

Einschreibung (Geschätzt)

540

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Garmisch-Partenkirchen, Deutschland, 82467
        • Klinikum Garmisch-Partenkirchen GmbH
      • Salouël, Frankreich, 80480
        • Sevice de Chirurgie Orthoedique et Traumatologique
    • Cedex
      • Brest, Cedex, Frankreich, 29285
        • CHU de la Cavale Blanche
      • Cork, Irland, T12 X23H
        • South Infirmary Victoria University Hospital
    • Alberta
      • Calgary, Alberta, Kanada, T2N 2T9
        • Foothills Medical Centre, University of Calgary
      • Christchurch, Neuseeland, 8083
        • University of Otago
    • North Brabant
      • Helmond, North Brabant, Niederlande, 5707 HA
        • Elkerliek Ziekenhuis
    • Colorado
      • Denver, Colorado, Vereinigte Staaten, 80210
        • Colorado Joint Replacement
    • Florida
      • DeLand, Florida, Vereinigte Staaten, 32720
        • Florida Research Associates
    • New Hampshire
      • Lebanon, New Hampshire, Vereinigte Staaten, 03756
        • Dartmouth-Hitchcock Medical Center
      • New London, New Hampshire, Vereinigte Staaten, 03257
        • New London Hospital
    • New Jersey
      • Egg Harbor, New Jersey, Vereinigte Staaten, 08234
        • Rothman Institute
    • New York
      • Brooklyn, New York, Vereinigte Staaten, 11203
        • SUNY downstate Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, Vereinigte Staaten, 27599
        • UNC Chapel Hill
    • Tennessee
      • Kingsport, Tennessee, Vereinigte Staaten, 37660
        • Associated Orthopaedics of Kingsport
    • Texas
      • Lubbock, Texas, Vereinigte Staaten, 49416
        • Texas Tech University Heath Science Center
    • Virginia
      • Newport News, Virginia, Vereinigte Staaten, 23606
        • Hampton Roads Orthopaedics and Sports Medicine
      • Nottingham, Vereinigtes Königreich, NG5 1PB
        • Nottingham University Hospitals NHS Trust
    • Lancashire
      • Wigan, Lancashire, Vereinigtes Königreich, WN6 9EP
        • Wrightington Hospital
    • Upper Austria
      • Ried im Innkreis, Upper Austria, Österreich, 4910
        • Krankenhaus der Barmherzigen Schwestern Ried im Innkreis

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

22 Jahre bis 80 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Subject is male or female and between the ages of 22 and 80 years at the time of surgery, inclusive.
  • Subject was diagnosed with NIDJD.
  • Subject, in the opinion of the Investigator, is a suitable candidate for cementless primary TKA using the devices described in this CIP with either resurfaced or non-resurfaced patellae.
  • Subject that is willing to give voluntary, written informed consent to participate in this clinical investigation and authorize the transfer of his/her information to the Sponsor
  • Subject is currently not bedridden
  • Subject, in the opinion of the Investigator, is able to understand this clinical investigation and is willing and able to perform all study procedures and follow-up visits and co-operate with investigational procedures.
  • Subject is able to read, and comprehend the Informed Consent Document as well as complete the required PROs in either English or one of the available translations.

Exclusion Criteria:

  • The Subject is a woman who is pregnant or lactating.
  • Contralateral knee has already been enrolled in this study .
  • Subject had a contralateral amputation.
  • Previous partial knee replacement (unicompartmental, bicompartmental or patellofemoral joint replacement), patellectomy, high tibial osteotomy or primary TKA in affected knee.
  • Subject is currently diagnosed with radicular pain from the spine that radiates into the limb to receive TKA.
  • Subject has participated in a clinical investigation with an investigational product (drug or device) in the last three (3) months.
  • Subject is currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
  • Subject, in the opinion of the Investigator, is a drug or alcohol abuser (in the last 5 years) or has a psychological disorder that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
  • Subject was diagnosed and is taking prescription medications to treat a muscular disorder that limits mobility due to severe stiffness and pain such as fibromyalgia or polymyalgia.
  • Subject has a significant neurological or musculoskeletal disorder(s) or disease that may adversely affect gait or weight bearing (e.g., muscular dystrophy, multiple sclerosis, Charcot disease).
  • Subject is suffering from inflammatory arthritis (e.g., rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, etc.).
  • Subject has a medical condition with less than five (5) years life expectancy.
  • Uncontrolled gout

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: ATTUNE Cementless RP TKA

Subjects will receive a cementless, rotating platform total knee arthroplasty

Patients will undergo a primary total knee replacement using one of the two configurations of the ATTUNE Cementless knee (CR RP or PS RP)

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Patient-reported Outcome: Knee Injury and Osteoarthritis Outcome Score Activities of Daily Living (KOOS ADL)
Zeitfenster: Minimum 2 years (670-1033 days after surgery)

The Knee injury and Osteoarthritis Outcome Score (KOOS) is a patient self-administered questionnaire that consists of 42 questions and include the WOMAC Osteoarthritis index. The KOOS consists of 5 subscales: pain, other symptoms, activities of daily living (ADL), sport and recreational function and knee related quality of life. Each question has 5 Likert-like response options. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.

Minimum 2 years (670-1033 days after surgery)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Patient-reported Outcome: Pre-surgical/Post-surgical Patient's Knee Implant Performance (PKIP)
Zeitfenster: Minimum 2 years (670-1033 days after surgery)

The Pre Surgical and/or Post-surgical Patient's Knee Implant Performance (PKIP) questionnaire is a patient self-administered questionnaire that consists of 25 questions relating to the patient's awareness of their knee. Questions include the patient's self-confidence about the current status of their knee performance, stability, and overall satisfaction. Each question has a 5, 6 or 10 Likert- like response option.

Minimum 2 years (670-1033 days after surgery)
Patient-reported Outcome: Knee Injury and Osteoarthritis Outcome Score (KOOS)
Zeitfenster: Minimum 2 years (670-1033 days after surgery)

The Knee injury and Osteoarthritis Outcome Score (KOOS) is a patient self-administered questionnaire that consists of 42 questions and include the WOMAC Osteoarthritis index. The KOOS consists of 5 subscales: pain, other symptoms, activities of daily living (ADL), sport and recreational function and knee related quality of life. Each question has 5 Likert-like response options. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.

Minimum 2 years (670-1033 days after surgery)
Combination of Patient-reported and Clinical-reported Outcome: Knee Society 2011
Zeitfenster: Minimum 2 years (670-1033 days after surgery)

The Knee Society Score is a self-administered questionnaire. The subject completes questions regarding: Symptoms (3 questions), Patient Satisfaction (5 questions), Patient Expectations (3 questions), Functional Activities (5 questions), Standard Activities (6 questions), Advanced Activities (5 questions), and Discretionary Knee Activities ( 4 questions). The surgeon completes questions regarding objective knee indicators. Likert responses are used, typically with five response options.

Minimum 2 years (670-1033 days after surgery)
Patient Reported Outcome: EuroQol 5D 3L questionnaire (EQ-5D-3L)
Zeitfenster: Minimum 2 years (670-1033 days after surgery)

EuroQol 5D 3L questionnaire is a standardized instrument for use as a measure of health outcome that is designed for completion by the subject.

Minimum 2 years (670-1033 days after surgery)
Modified VAS Pain Score: Pain and Satisfaction
Zeitfenster: Minimum 2 years (670-1033 days after surgery)

VAS Pain Score is a standardized instrument for use as a measure of pain and satisfaction that is designed for completion by the subject. This modified version has scores that are discrete numbers rather than a continual scale

Minimum 2 years (670-1033 days after surgery)
Type and Frequency of Adverse Events (AEs) for all enrolled subjects
Zeitfenster: Pre-op (-90 to -1 days before surgery), 6 weeks (1-90 days after surgery), 6 months (91-303 days after surgery), minimum 1 year (304-669 days after surgery), minimum 2 years (670-1033 days after surgery), minimum 5 years (1764-2190 days after surgery)

All Serious AEs must be reported to Sponsor. All device-related or procedure-related adverse events must be reported to Sponsor.

Pre-op (-90 to -1 days before surgery), 6 weeks (1-90 days after surgery), 6 months (91-303 days after surgery), minimum 1 year (304-669 days after surgery), minimum 2 years (670-1033 days after surgery), minimum 5 years (1764-2190 days after surgery)
Survivorship
Zeitfenster: Minimum 2 years (670-1033 days after surgery)

Kaplan-Meier survival analysis will be used to calculate the survivorship of all 2 configurations (CR RP, PS RP)

Minimum 2 years (670-1033 days after surgery)
Survivorship
Zeitfenster: Minimum 5 years (1764-2190 days after surgery)

Kaplan-Meier survival analysis will be used to calculate the survivorship of all 2 configurations (CR RP, PS RP)

Minimum 5 years (1764-2190 days after surgery)
Implant fixation: Radiographic assessment of bone-implant interface performance
Zeitfenster: 6 weeks (1-90 days after surgery)

Radiographic success is defined as: absence of progressive radiolucent lines greater than or equal to 2mm in any one zone; absence of lytic lesions in any zone; absence of individual component position change >3degrees in any plane.

6 weeks (1-90 days after surgery)
Implant fixation: Radiographic assessment of bone-implant interface performance
Zeitfenster: 6 months (91-303 days after surgery)

Radiographic success is defined as: absence of progressive radiolucent lines greater than or equal to 2mm in any one zone; absence of lytic lesions in any zone; absence of individual component position change >3degrees in any plane.

6 months (91-303 days after surgery)
Implant fixation: Radiographic assessment of bone-implant interface performance
Zeitfenster: Minimum 1 year (304-669 days after surgery).

Radiographic success is defined as: absence of progressive radiolucent lines greater than or equal to 2mm in any one zone; absence of lytic lesions in any zone; absence of individual component position change >3degrees in any plane.

Minimum 1 year (304-669 days after surgery).
Implant fixation: Radiographic assessment of bone-implant interface performance
Zeitfenster: Minimum 2 years (670-1033 days after surgery)

Radiographic success is defined as: absence of progressive radiolucent lines greater than or equal to 2mm in any one zone; absence of lytic lesions in any zone; absence of individual component position change >3degrees in any plane.

Minimum 2 years (670-1033 days after surgery)
Evaluate changes in femoral component and tibial component alignment
Zeitfenster: Minimum 2 years (670-1033 days after surgery)

Radiographs will be reviewed by an independent radiographic reviewer (IRR) in order to minimize bias of radiographic outcomes. Data from the IRR radiographic evaluations will be used to evaluate femoral and tibial component alignment over time.

Minimum 2 years (670-1033 days after surgery)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Sukhjeet Kaur, Sponsor GmbH

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. September 2016

Primärer Abschluss (Geschätzt)

1. September 2027

Studienabschluss (Geschätzt)

1. September 2027

Studienanmeldedaten

Zuerst eingereicht

19. Juli 2016

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

20. Juli 2016

Zuerst gepostet (Geschätzt)

21. Juli 2016

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

3. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 14022

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .